» Articles » PMID: 33257533

Microbial Lipid A Remodeling Controls Cross-Presentation Efficiency and CD8 T Cell Priming by Modulating Dendritic Cell Function

Overview
Journal Infect Immun
Date 2020 Dec 1
PMID 33257533
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The majority of Gram-negative bacteria elicit a potent immune response via recognition of lipid A expressed on the outer bacterial membrane by the host immune receptor Toll-like receptor 4 (TLR4). However, some Gram-negative bacteria evade detection by TLR4 or alter the outcome of TLR4 signaling by modification of lipid A species. Although the role of lipid A modifications on host innate immunity has been examined in some detail, it is currently unclear how lipid A remodeling influences host adaptive immunity. One prototypic Gram-negative bacterium that modifies its lipid A structure is , an anaerobic pathobiont that colonizes the human periodontium and induces chronic low-grade inflammation that is associated with periodontal disease as well as a number of systemic inflammatory disorders. produces dephosphorylated and deacylated lipid A structures displaying altered activities at TLR4. Here, we explored the functional role of lipid A modifications on TLR4-dependent innate and adaptive immune responses in mouse bone marrow-derived dendritic cells (BMDCs). We discovered that lipid A 4'-phosphate removal is required for to evade BMDC-dependent proinflammatory cytokine responses and markedly limits the bacterium's capacity to induce beta interferon (IFN-β) production. In addition, lipid A 4'-phosphatase activity prevents canonical bacterium-induced delay in antigen degradation, which leads to inefficient antigen cross-presentation and a failure to cross-prime CD8 T cells specific for a -associated antigen. We propose that lipid A modifications produced by this bacterium alter host TLR4-dependent adaptive immunity to establish chronic infections associated with a number of systemic inflammatory disorders.

Citing Articles

Across-cancer specific immune responses induced by nanovaccines or microvaccines to prevent different cancers and cancer metastasis.

Diao L, Ma L, Cheng J, Pan Y, Peng Z, Zhang L iScience. 2022; 25(12):105511.

PMID: 36437877 PMC: 9682363. DOI: 10.1016/j.isci.2022.105511.


Evaluating clinical utility of subgingival and salivary endotoxin activity levels as periodontal biomarkers.

Zaric S, Strachan A, Kurushima Y, Dong A, McIlwaine C, Harrington Z Front Oral Health. 2022; 3:1029806.

PMID: 36389276 PMC: 9663459. DOI: 10.3389/froh.2022.1029806.

References
1.
Arvikar S, Collier D, Fisher M, Unizony S, Cohen G, McHugh G . Clinical correlations with Porphyromonas gingivalis antibody responses in patients with early rheumatoid arthritis. Arthritis Res Ther. 2013; 15(5):R109. PMC: 3978628. DOI: 10.1186/ar4289. View

2.
Papadopoulos G, Weinberg E, Massari P, Gibson 3rd F, Wetzler L, Morgan E . Macrophage-specific TLR2 signaling mediates pathogen-induced TNF-dependent inflammatory oral bone loss. J Immunol. 2012; 190(3):1148-57. PMC: 3549226. DOI: 10.4049/jimmunol.1202511. View

3.
Miles B, Scisci E, Carrion J, Sabino G, Genco C, Cutler C . Noncanonical dendritic cell differentiation and survival driven by a bacteremic pathogen. J Leukoc Biol. 2013; 94(2):281-9. PMC: 3714568. DOI: 10.1189/jlb.0213108. View

4.
Jain S, Coats S, Chang A, Darveau R . A novel class of lipoprotein lipase-sensitive molecules mediates Toll-like receptor 2 activation by Porphyromonas gingivalis. Infect Immun. 2013; 81(4):1277-86. PMC: 3639599. DOI: 10.1128/IAI.01036-12. View

5.
Duncan M, Nakao S, Skobe Z, Xie H . Interactions of Porphyromonas gingivalis with epithelial cells. Infect Immun. 1993; 61(5):2260-5. PMC: 280837. DOI: 10.1128/iai.61.5.2260-2265.1993. View